Search research articles
Contact Us
Filters
Showing results (471-480 of 666) with videos related to
Page
of 67
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
August 2, 2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
Daniel W Coyne, Ajay K Singh, Renato D Lopes, et al.
Journal of the American College of Cardiology
|
May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Javed Butler, Milton Packer, Tariq Jamal Siddiqi, et al.
Molecular Genetics and Metabolism
|
April 22, 2008
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3
Anouk C Vedder, Frank Breunig, Wilma E Donker-Koopman, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
European Heart Journal
|
March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Michael Böhm, Javed Butler, Andrew Coats, et al.
JAMA Cardiology
|
January 3, 2024
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials
Nikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, et al.
Kidney International
|
November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
Bettina J Kraus, Matthew R Weir, George L Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry
Christoph Wanner, João P Oliveira, Alberto Ortiz, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 13, 2026
Combination Treatment for Management of Chronic Kidney Disease and Type 2 Diabetes: A Review and Practical Guidance
Mai Mohsen, Tae Won Yi, Labib Faruque, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
Natalie Staplin, Richard Haynes, William G Herrington, et al.
Page
of 67
Search research articles
Search
Showing results (471-480 of 666) with videos related to
Sort By:
Page
of 67
Clinical Journal of the American Society of Nephrology : CJASN
|
August 2, 2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
Daniel W Coyne, Ajay K Singh, Renato D Lopes, et al.
Journal of the American College of Cardiology
|
May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Javed Butler, Milton Packer, Tariq Jamal Siddiqi, et al.
Molecular Genetics and Metabolism
|
April 22, 2008
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3
Anouk C Vedder, Frank Breunig, Wilma E Donker-Koopman, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
European Heart Journal
|
March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Michael Böhm, Javed Butler, Andrew Coats, et al.
JAMA Cardiology
|
January 3, 2024
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials
Nikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, et al.
Kidney International
|
November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
Bettina J Kraus, Matthew R Weir, George L Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry
Christoph Wanner, João P Oliveira, Alberto Ortiz, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 13, 2026
Combination Treatment for Management of Chronic Kidney Disease and Type 2 Diabetes: A Review and Practical Guidance
Mai Mohsen, Tae Won Yi, Labib Faruque, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
Natalie Staplin, Richard Haynes, William G Herrington, et al.
Page
of 67